PURPOSE: To report the clinical settings, antibiotic susceptibilities, and outcomes of endophthalmitis caused by Streptococcus species. DESIGN: Retrospective, observational case series. METHODS: Single-center study evaluating all patients with culture-positive endophthalmitis caused by Streptococcus species between January 1, 2000, and December 31, 2011. RESULTS: Study criteria were met by 63 patients. The most common clinical settings were bleb associated (n = 17; 27%), after intravitreal injection (n = 16; 25%), and after cataract surgery (n = 13; 21%). The isolates were Streptococcus viridans (n = 47; 71%), Streptococcus pneumoniae (n = 13; 21%), and β-hemolytic Streptococci (n = 5; 8%). Sixty (95%) of 63 isolates were susceptible to vancomycin, 47 (98%) of 48 isolates were susceptible to ceftriaxone (third-generation cephalosporin), and 57 (93%) of 61 isolates were susceptible to levofloxacin (third-generation fluoroquinolone). Between the first and second half of the study, the minimal inhibitory concentration of antibiotics required to inhibit 90% of isolates increased by 1.5-fold for ceftriaxone and 2-fold for levofloxacin and remained the same for vancomycin. Initial treatment was vitreous tap (49; 78%) or pars plana vitrectomy (14; 22%); all received intravitreal antibiotics. Visual acuity outcomes were variable: best-corrected visual acuity was 20/400 or better in 16 (25%) patients and worse than 20/400 in 47 (75%) patients. Evisceration or enucleation was performed in 16 (25%) patients. CONCLUSIONS: Streptococcus isolates generally had high susceptibility rates to commonly used antibiotics. Higher antibiotic minimal inhibitory concentrations were required to inhibit 90% of isolates in vitro in the second half of the study period compared with the first half. Despite prompt treatment, most patients had poor outcomes.
PURPOSE: To report the clinical settings, antibiotic susceptibilities, and outcomes of endophthalmitis caused by Streptococcus species. DESIGN: Retrospective, observational case series. METHODS: Single-center study evaluating all patients with culture-positive endophthalmitis caused by Streptococcus species between January 1, 2000, and December 31, 2011. RESULTS: Study criteria were met by 63 patients. The most common clinical settings were bleb associated (n = 17; 27%), after intravitreal injection (n = 16; 25%), and after cataract surgery (n = 13; 21%). The isolates were Streptococcus viridans (n = 47; 71%), Streptococcus pneumoniae (n = 13; 21%), and β-hemolytic Streptococci (n = 5; 8%). Sixty (95%) of 63 isolates were susceptible to vancomycin, 47 (98%) of 48 isolates were susceptible to ceftriaxone (third-generation cephalosporin), and 57 (93%) of 61 isolates were susceptible to levofloxacin (third-generation fluoroquinolone). Between the first and second half of the study, the minimal inhibitory concentration of antibiotics required to inhibit 90% of isolates increased by 1.5-fold for ceftriaxone and 2-fold for levofloxacin and remained the same for vancomycin. Initial treatment was vitreous tap (49; 78%) or pars plana vitrectomy (14; 22%); all received intravitreal antibiotics. Visual acuity outcomes were variable: best-corrected visual acuity was 20/400 or better in 16 (25%) patients and worse than 20/400 in 47 (75%) patients. Evisceration or enucleation was performed in 16 (25%) patients. CONCLUSIONS:Streptococcus isolates generally had high susceptibility rates to commonly used antibiotics. Higher antibiotic minimal inhibitory concentrations were required to inhibit 90% of isolates in vitro in the second half of the study period compared with the first half. Despite prompt treatment, most patients had poor outcomes.
Authors: John J Miller; Ingrid U Scott; Harry W Flynn; William E Smiddy; Jean Newton; Darlene Miller Journal: Am J Ophthalmol Date: 2005-06 Impact factor: 5.258
Authors: G K Shah; J D Stein; S Sharma; A Sivalingam; W E Benson; C D Regillo; G C Brown; W Tasman Journal: Ophthalmology Date: 2000-03 Impact factor: 12.079
Authors: John J de Caro; Christopher N Ta; Hoai-Ky V Ho; Lorella Cabael; Nan Hu; Steven R Sanislo; Mark S Blumenkranz; Darius M Moshfeghi; Robert Jack; Herminia Miño de Kaspar Journal: Retina Date: 2008-06 Impact factor: 4.256
Authors: Suman Pilli; Athanasios Kotsolis; Richard F Spaide; Jason Slakter; K Bailey Freund; John Sorenson; James Klancnik; Michael Cooney Journal: Am J Ophthalmol Date: 2008-03-10 Impact factor: 5.258
Authors: Geraldine R Slean; Neal H Shorstein; Liyan Liu; John F Paschal; Kevin L Winthrop; Lisa J Herrinton Journal: Clin Exp Ophthalmol Date: 2017-01-31 Impact factor: 4.207
Authors: Jayanth Sridhar; Yoshihiro Yonekawa; Ajay E Kuriyan; Anthony Joseph; Benjamin J Thomas; Michelle C Liang; Nadim Rayess; Nidhi Relhan; Jeremy D Wolfe; Chirag P Shah; Andre J Witkin; Harry W Flynn; Sunir J Garg Journal: Retina Date: 2017-07 Impact factor: 4.256
Authors: Justin A Thornton; Nathan A Tullos; Melissa E Sanders; Granger Ridout; Yong-Dong Wang; Sidney D Taylor; Larry S McDaniel; Mary E Marquart Journal: Ophthalmic Res Date: 2015-03-12 Impact factor: 2.892
Authors: Nidhi Relhan; Thomas A Albini; Avinash Pathengay; Ajay E Kuriyan; Darlene Miller; Harry W Flynn Journal: Br J Ophthalmol Date: 2015-12-23 Impact factor: 4.638
Authors: Ajay E Kuriyan; Jayanth Sridhar; Harry W Flynn; Laura C Huang; Nicolas A Yannuzzi; William E Smiddy; Janet L Davis; Thomas A Albini; Audina M Berrocal; Darlene Miller Journal: Ophthalmol Retina Date: 2017 May-Jun